[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Kymera Therapeutics, Inc. Common Stock (KYMR)
Kymera Therapeutics announced pricing of an upsized $XXX million public offering following positive Phase 1b trial results for KT-621, aiming to rival Dupixent.
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for immuno-inflammatory diseases.
Kymera Therapeutics, Inc. Common Stock uses the ticker $KYMR for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Kymera Therapeutics, Inc. Common Stock (KYMR) social dominance hit XXXXXX which is XXX% higher than it's daily average.
- Kymera Therapeutics, Inc. Common Stock (KYMR) trading volume is up XXXXXX% from the previous week.
- Kymera Therapeutics, Inc. Common Stock (KYMR) market cap is up XXXXXX% from the previous year.
- Kymera Therapeutics, Inc. Common Stock (KYMR) social dominance is up 1352% from the previous X months.
- Kymera Therapeutics, Inc. Common Stock (KYMR) creators is up XXXXXX% from the previous week.
- Kymera Therapeutics, Inc. Common Stock (KYMR) engagements is up 2807.96% from the previous week.
- Kymera Therapeutics, Inc. Common Stock (KYMR) mentions is up XXXXXX% from the previous week.
- Kymera Therapeutics, Inc. Common Stock (KYMR) posts created is up 9500% from the previous week.
- Kymera Therapeutics, Inc. Common Stock entered the top XX AltRank™ for the first time
- Kymera Therapeutics, Inc. Common Stock Price hit a 52-Week high of $XXXXXX for the hour
- Kymera Therapeutics, Inc. Common Stock Price hit an all time of $XXXXXX for the hour
- Kymera Therapeutics, Inc. Common Stock Engagements hit a 52-Week high of XXXXXXX for the day
- Kymera Therapeutics, Inc. Common Stock Engagements hit an all time of XXXXXXX for the day
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock price has hit a 52-week and all-time high, driven by positive clinical trial data for KT-621 and analyst upgrades, despite a proposed share offering which may temper immediate gains.
24-Hour: XXXX% 7-Day: XXXXX% 30-Day: XXXXX%
1-Year High: $XXXXX on 2025-12-08
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
Kymera Therapeutics, Inc. Common Stock (KYMR) is currently AltRank #504 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX -XXX
X Month: XXX -XXX
X Months: XXX -XXX
X Year: XXX -XXX
1-Year High: XXXXX on 2025-08-06
1-Year Low: XX on 2025-01-11
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -XX
X Month: XX -XX
X Months: XX +2
X Year: XX -XX
1-Year High: XX on 2025-01-14
1-Year Low: X on 2025-08-06
Engagements: XXXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
X Week: XXXXXXX +2,808%
X Month: XXXXXXX +561%
X Months: XXXXXXXXX +55%
X Year: XXXXXXXXX +120%
1-Year High: XXXXXXX on 2025-12-08
1-Year Low: XXX on 2025-02-03
Engagements by network (24h): News: XX Reddit: XX TikTok: XX X: XXXXXX YouTube: X
Mentions: XXX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XX
X Week: XXXXX +632%
X Month: XXXXX +318%
X Months: XXXXX +285%
X Year: XXXXX +337%
1-Year High: XXXXX on 2025-07-06
1-Year Low: XX on 2025-01-28
Mentions by network (24h): News: XX Reddit: XX TikTok: X X: XXXXX YouTube: X
Creators: XXX (24h)
Creators 24-Hour Time-Series Raw Data
XXX unique social accounts have posts mentioning Kymera Therapeutics, Inc. Common Stock (KYMR) in the last XX hours which is down XX% from XXX in the previous XX hours
Daily Average: XX
X Week: XXX +852%
X Month: XXX +421%
X Months: XXXXX +450%
X Year: XXXXX +335%
1-Year High: XXX on 2025-07-06
1-Year Low: X on 2025-01-28
The most influential creators that mention Kymera Therapeutics, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BowTiedBiotech | X | XXXXXX | X | XXXXX |
| @HOThomasWPhelps | X | XXXXX | X | XXXXX |
| @BioStocks | X | XXXXXX | X | XXXXX |
| @Andre_AGTC | X | XXXXX | X | XXXXX |
| @A_May_MD | X | XXXXXX | X | XXX |
| @seedy19tron | X | XXXXX | X | XXX |
| @adamfeuerstein | X | XXXXXXX | X | XXX |
| @PersimmonTI | X | XXXXXX | X | XXX |
| @monaco_biotech | X | XXXXX | X | XXX |
| @marketwirenews | XX | XXXXXX | X | XXX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% no change
X Month: XX% +26%
X Months: XX% -X%
X Year: XX% +37%
1-Year High: XXX% on 2025-01-30
1-Year Low: XX% on 2025-04-13
Most Supportive Themes:
- Positive Analyst Commentary and Biotech Sector Outlook: (40%) Analysts are discussing Kymera's approach and comparing it to competitors, with positive sentiment around the biotech sector.
- Mentions of KYMR in conjunction with other Biotech Stocks: (30%) Posts frequently mention KYMR alongside other biotech stocks, indicating potential sector-wide interest and comparisons.
- Positive Sentiment and High Engagement on Social Media: (20%) Overall sentiment is positive, with high engagement on posts mentioning KYMR, especially from influential creators.
Most Critical Themes:
- Concerns about Efficacy and Side Effects: (10%) Some posts raise concerns about the efficacy of KYMR's treatments compared to competitors and potential side effects.
Social Dominance: XXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.046%
X Month: XXXXX% +0.066%
X Months: XXXXX% +0.06%
X Year: XXXXX% +0.057%
1-Year High: XXXX% on 2025-12-09
1-Year Low: XXXXXX% on 2025-04-08
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-12-08
1-Year Low: XXXXXXX% on 2025-03-19
Market Cap: $XXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$32%
X Month: $XXXXXXXXXXXXX +$39%
X Months: $XXXXXXXXXXXXX +$107%
X Year: $XXXXXXXXXXXXX +$118%
1-Year High: $XXXXXXXXXXXXX on 2025-12-08
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08
Top Kymera Therapeutics, Inc. Common Stock News
Top news links shared on social in the last XX hours
Showing a maximum of X news posts for non-authenticated requests. Use your API key in requests for full results.
"Kymera Therapeutics raises $602M after clinical trial win - Boston Business Journal"
News Link @bizjournals 2025-12-10T20:13Z 228.6M followers, XXX engagements
"Kymera Therapeutics stock price target raised to $XXX from $XX at Stifel By Investing.com"
News Link @Investingcom 2025-12-08T22:11Z 1.4M followers, XXX engagements
"Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621 a First-in-Class Oral STAT6 Degrader in Patients with Moderate to Severe Atopic Dermatitis"
News Link @YahooFinance 2025-12-08T12:06Z 228.6M followers, 19.4K engagements
Top Kymera Therapeutics, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$KYMR -XXXX% today as Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621 a First-in-Class Oral STAT6 Degrader for the Treatment of Atopic Dermatitis More Info:"
X Link @OzmosiHealth 2025-12-11T17:37Z 3014 followers, XX engagements
"Breaking News: $KYMR KYMR Price Target Alert: $XXXXXX. Issued by Mizuho Securities @grok please provide the finance card for $KYMR"
X Link @marketwirenews 2025-12-11T17:00Z 60.7K followers, XXX engagements
"JUST IN: $KYMR Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621 a First-in-Class Oral STAT6 Degrader for the Treatment of Atopic Dermatitis @grok please provide the finance card for $KYMR"
X Link @marketwirenews 2025-12-11T16:40Z 60.7K followers, XXX engagements
"Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621 a First-in-Class Oral STAT6 Degrader for the Treatment of Atopic Dermatitis"
Reddit Link @Quantisnow 2025-12-11T13:46Z X followers, X engagements